Navigation Links
Edison highlights the potential of GW Pharmaceuticals' cannabinoid pipeline and furthers its US healthcare presence

LONDON, Dec. 10, 2013 /PRNewswire/ -- Edison's ADR outlook note, Orphan opportunities, highlights that 2014 could be transformative for GW as its pipeline delivers important clinical milestones. GW's acceleration of orphan programmes in childhood epilepsy (Epidiolex) and primary brain cancer (THC:CBD combination) should generate clinical data and Phase II starts for both indications. In addition, the company's lead programme, Sativex, is approaching key value inflection points including Phase III cancer pain data (Q414) and the US Phase III start in MS spasticity (H214).

Edison's healthcare team forecasts peak sales for Epidiolex in Dravet syndrome (DS) of $288m, THC/CBD (GBM) of $246m and GWP42004 (type 2 diabetes) of $1,025m. It projects Sativex peak sales potential of $814m – MS Spasticity at $278m (US $176m, ex-US $102m) and cancer pain at $536m (US $350m, ex-US $186m).

Edison's revised DCF valuation is $715m, or $48.30 per ADR, following the inclusion of R&D pipeline programmes. Positive data from physician-led studies of Epidiolex (mid-2014 onwards) would see the DCF rise to $818m or $55.30/ADR. Positive Sativex Phase III data in cancer pain (late 2014) would see the DCF rise further to $867m or $58.60/ADR. GW's remaining R&D programmes (epilepsy, ulcerative colitis and schizophrenia) offer pure upside to Edison's valuation.

For the full report see:

About Edison Investment Research This continued ADR coverage on GW Pharmaceuticals is part of a programme of research coverage on pharmaceutical companies exposed to global market opportunities. Edison provides detailed research on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website

Edison is authorised and regulated by the Financial Services Authority ( Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact:Lala GregorekEdison Investment Research+44 (0)20 3681 2527Robin DavisonEdison Investment Research+44 (0)20 3077 5737healthcare@edisongroup.comAbout GW Pharmaceuticals  GW Pharmaceuticals is a UK specialty pharma company focused on developing cannabinoids as pharmaceuticals. Lead product Sativex is marketed in a number of European countries for multiple sclerosis-associated spasticity.

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
10. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
11. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Post Your Comments:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):